

**PCT**WORLD INTELLECTUAL PROPE  
International Bu

## INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9604908A1

(51) International Patent Classification n 6 :

A61K 31/43, 9/20

A1

(11) International Publication Number:

WO 96/04908

(43) International Publication Date: 22 February 1996 (22.02.96)

(21) International Application Number: PCT/EP95/03151

(22) International Filing Date: 8 August 1995 (08.08.95)

(30) Priority Data:  
9416600.6 17 August 1994 (17.08.94) GB(71) Applicant (for all designated States except US): SMITHKLINE  
BEECHAM PLC [GB/GB]; New Horizons Court, Brend-  
ford, Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RIVETT, Ernest, Li-  
onel, Gilbert [GB/GB]; SmithKline Beecham Pharmaceu-  
ticals, Clarendon Road, Worthing, West Sussex BN14 8QH  
(GB). GRIMMETT, Francis, Walter [GB/GB]; SmithKline  
Beecham Pharmaceuticals, Clarendon Road, Worthing, West  
Sussex BN14 8QH (GB). HARTNELL, Michael, William  
[GB/GB]; SmithKline Beecham Pharmaceuticals, Clarendon  
Road, Worthing, West Sussex BN14 8QH (GB).(74) Agent: WALKER, Ralph, Francis; SmithKline Beecham,  
Corporate Intellectual Property, SB House, Great West  
Road, Brentford, Middlesex TW8 9BD (GB).(81) Designated States: JP, US, European patent (AT, BE, CH, DE,  
DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.

(54) Title: PHARMACEUTICAL FORMULATION CONTAINING AMOXYCILLIN AND POTASSIUM CLAVULANATE

## (57) Abstract

Pharmaceutical formulations for oral administration, comprising a matrix which comprises a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor, granules in a delayed release form dispersed within the matrix, which comprise a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor, the overall tablet formulation including a  $\beta$ -lactam antibiotic and a  $\beta$ -lactamase inhibitor.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Pharmaceutical formulation containing  
Amoxycillin and Potassium clavulanate

This invention relates to pharmaceutical formulations for oral administration, comprising an antibiotic and a  $\beta$ -lactamase inhibitor.

5 Oral formulations of this type are known, but generally need to be administered three times daily. It is desirable to produce such a formulation in a delayed or sustained release form which may be suitable for less frequent administration. A particularly effective  $\beta$ -lactamase inhibitor is the known compound clavulanic acid and its derivatives (hereinafter collectively termed  
10 "clavulanate" unless otherwise specifically identified), especially the potassium salt of clavulanic acid.

The invention therefore provides a pharmaceutical tablet formulation, comprising:  
a matrix which comprises a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -  
15 lactamase inhibitor,  
and dispersed within said matrix, granules in a delayed release form ("delayed release granules") which comprise a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor,  
the overall tablet formulation including a  $\beta$ -lactam antibiotic and a  $\beta$ -lactamase  
20 inhibitor.

The matrix preferably includes a  $\beta$ -lactamase inhibitor.

The granules may optionally also include a  $\beta$ -lactamase inhibitor in combination with the  $\beta$ -lactam antibiotic.

The matrix may also include dispersed within it granules ("rapid release  
25 granules"), in a form which release their content more rapidly than the delayed-release granules, which comprise a  $\beta$ -lactam antibiotic, optionally in combination with a  $\beta$ -lactamase inhibitor.

Preferred  $\beta$ -lactam antibiotics are penicillins and cephalosporins, in particular amoxycillin, for example in the form of amoxycillin trihydrate. A  
30 preferred  $\beta$ -lactamase inhibitor is clavulanate, particularly potassium clavulanate. In the matrix and those granules which contain a  $\beta$ -lactamase inhibitor the ratio antibiotic :  $\beta$ -lactamase inhibitor may vary independently between wide limits, in the case of amoxycillin : clavulanate for example varying between 1 : 1 to 30 : 1, for example amoxycillin : clavulanate between 1 : 1 to 12 : 1, e.g 2 : 1, 3 : 1, 4 :  
35 1, 5 : 1, 6 : 1, 7 : 1 or 8 : 1 inclusive expressed as the equivalent weight ratios of the parent free acids. In the overall tablet formulation the ratio antibiotic :  $\beta$ -lactamase inhibitor may also vary between similarly broad limits, for example between 1 : 1 to 30 : 1, for example between 1 : 1 to 12 : 1, e.g 2 : 1, 3 : 1, 4 : 1, 5 : 1, 6 : 1, 7 : 1 or 8 : 1 inclusive.

The matrix may suitably comprise a mixture of amoxycillin and potassium clavulanate in a ratio amoxycillin : clavulanate between 2 : 1 to 8 : 1, for example between 2 : 1 and 4 : 1 inclusive.

5 In one form of the tablet formulation of the invention, the tablet has a matrix which comprises amoxycillin and clavulanate, dispersed within which are delayed release granules which comprise amoxycillin and clavulanate. These granules may suitably comprise amoxycillin and potassium clavulanate in a ratio amoxycillin : clavulanate between 2 : 1 to 8 : 1 inclusive, for example around  $4 : 1 \pm 10\%$ .

10 In this first form of the tablet the overall distribution of the antibiotic and  $\beta$ -lactamase inhibitor between the matrix : granules may independently suitably vary between 2.5 : 1 to 1 : 2.5. Suitably the distribution of matrix amoxycillin : granule amoxycillin is around  $1 : 1.5 \pm 10\%$ , and the distribution of matrix clavulanate : granule clavulanate is around  $1.5 : 1 \pm 10\%$ .

15 In a second form of the tablet formulation of the invention, the tablet has a matrix which comprises amoxycillin and clavulanate, dispersed within which are delayed release granules which comprise amoxycillin, and rapid release granules which comprise amoxycillin.

20 In this second form of the tablet the overall distribution of the amoxycillin between the matrix plus rapid release granules : delayed release granules may vary between 2.5 : 1 and 1 : 2.5. Suitably the distribution may be around  $1 : 1.5 \pm 10\%$ . Suitably the distribution of amoxycillin between rapid release granules : matrix : delayed release granules may be around 1 : 1 - 2 : 2 - 6.

25 The matrix may comprise a compact of compressed ingredients including the antibiotic and optionally present  $\beta$ -lactamase inhibitor. In addition to antibiotic and optionally present  $\beta$ -lactamase inhibitor the matrix may contain conventional additives. Appropriate additives in such a tablet may comprise diluents such as calcium carbonate, magnesium carbonate, dicalcium phosphate or mixtures thereof, binders such as hydroxypropyl-methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, pre-  
30 gelatinised starch or gum acacia or mixtures thereof, disintegrants such as cross-linked polyvinylpyrrolidone, sodium starch glycollate, croscarmellose sodium or mixtures thereof, lubricants, such as magnesium stearate or stearic acid, glidants or flow aids, such as colloidal silica, talc or starch, and stabilisers such as desiccating amorphous silica, colouring agents,  
35 flavours etc..

The granules may be made by a conventional granulating process as known in the art. Preferably the granules are made by a procedure of dry granulation of the granule components, for example slugging then milling, or by roller compaction then milling. The granules may include conventional additives introduced as a result

of the granulation process, e.g. lubricants such as magnesium stearate, in conventional quantities, e.g. ca. 0.5 - 1 wt% of magnesium stearate. Suitably the granules are of 10 - 40 mesh size, for example 16 - 30 mesh size.

To form delayed release granules, the granules are preferably coated with a coating layer of a dissolution-retarding coating. In their uncoated form such granules are rapid release granules, which release their content more rapidly than coated granules. The dissolution-retarding coating may be a polymeric material, for example an enteric polymer (the term "enteric polymer" is a term of the art referring to a polymer which is preferentially soluble in the less acid environment of the intestine relative to the more acid environment of the stomach).

An enteric coating may be an essentially conventional coating material known for enteric coating of antibiotic granules, for example enteric polymers such as cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetate phthalate, polyvinylbutyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono-ester copolymer, methyl acrylate-methacrylic acid copolymer, methacrylate-methacrylic acid-octyl acrylate copolymer, etc. These may be used either alone or in combination, or together with other polymers than those mentioned above. The enteric coating may also include insoluble substances which are neither decomposed nor solubilized in living bodies, such as alkyl cellulose derivatives such as ethyl cellulose, crosslinked polymers such as styrene-divinylbenzene copolymer, polysaccharides having hydroxyl groups such as dextran, cellulose derivatives which are treated with bifunctional crosslinking agents such as epichlorohydrin, dichlorohydrin, 1, 2-, 3, 4-diepoxybutane, etc. The enteric coating may also include starch and/or dextrin.

Preferred enteric coating materials are the commercially available "Eudragit" (Trade Mark) enteric polymers, such as "Eudragit L" (Trade Mark), "Eudragit S" (Trade Mark) and "Eudragit NE" (Trade Mark) used either alone or with a plasticiser. Such coatings are normally applied using a liquid medium, and the nature of the plasticiser, depends upon whether the medium is aqueous or non-aqueous. Aqueous plasticisers include propylene glycol or "Citroflex" or Citroflex A2" (Trade Marks) (mainly triethyl citrate or acetyl triethyl citrate). Non-aqueous plasticisers include these, and also diethyl and dibutyl phthalate and dibutyl sebacate.

The quantity of plasticiser included will be apparent to those skilled in the art. The enteric coating may also include an anti-tack agent such as talc, silica or glyceryl monostearate. The quantity of plasticiser and anti-tack agent may be generally conventional to the art. Typically the coating may include around 10 - 25

wt. % plasticiser and up to around 50 wt% of anti tack agent, e.g. 5 - 20 wt. % of anti-tack agent.

The enteric coating may be applied to the granules by dissolving or suspending the enteric coating materials in a suitable medium, such as water, methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, methylene chloride, ethylene chloride, ethyl acetate, etc. or mixtures thereof, and the resultant solution or suspension may be sprayed on the granules to coat them, followed by drying sufficiently with an air flow and screening.

In the case of the preferred enteric coating material referred to above, the enteric coating material may be dissolved or suspended in a solvent for example water and coated onto the granules using a fluidised bed system. If water is used, preferably an anti-foaming agent such as activated polymethylsiloxane is also included.

The dissolution-retarding coating layer may be applied sequentially to the granules, in a batch or continuous process. In a batch process the granules may be removed from the equipment being used to apply the surrounding layer and coated later. In a continuous process, after the surrounding layer had been deposited on the granules the nature of the coating solution may be changed after application of a suitable quantity of the surrounding layer.

Suitably the dissolution-retarding, e.g enteric polymer, coating layer may comprise 15 - 30 wt. % of the overall granule weight.

The tablet formulation of the invention provides a sustained or delayed release effect following oral ingestion, as the antibiotic and optionally present  $\beta$ -lactamase inhibitor in the matrix, and rapid release granules (when present) are relatively rapidly released in the stomach, whilst the antibiotic and  $\beta$ -lactamase inhibitor in the delayed release granules are relatively slowly released, for example in the intestine as an enteric coating on the granules dissolves preferentially in the more alkaline environment of the intestine.

Methods of compacting matrix materials and granules to form a tablet of the invention are well known in the art. For example the matrix material in a powdered or granulated form and the granules may be screened and blended, and the mixture may then be compressed into a tablet in a conventional manner, e.g in a tableting press. Some loss of integrity of the granule structure, e.g crushing of the granules, or disruption of a dissolution-retarding coating layer may occur during compaction but this may be reduced by the use of known compaction aids such as starch and/or microcrystalline celluloses. Tablets containing such crushed granules are included within the scope of this invention.

The invention therefore also provides a method of preparing a pharmaceutical formulation as described herein, comprising the steps of forming a matrix which comprises a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor, and dispersed within said matrix, delayed release granules  
5 which comprise a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor, the overall tablet formulation including a  $\beta$ -lactam antibiotic and a  $\beta$ -lactamase inhibitor.

The above-mentioned formulations for oral administration may contain quantities of antibiotic and  $\beta$ -lactamase inhibitor up to the maximum amount  
10 allowed by regulatory authorities. For example in the case of amoxycillin and clavulanate the total amount of amoxycillin may be  $875 \pm 100$  mg (expressed as the parent free acids), and of clavulanate 250 mg for a daily dose, divided up between one or more unit dosage forms. Unit dosage forms of the tablet of the invention may for example contain nominally 250, 500 or 750 mg of amoxycillin, and a  
15 quantity of potassium clavulanate corresponding to the above-mentioned weight ratios of clavulanate.

Clavulanic acid and its derivatives, e.g. salts such as potassium clavulanate are extremely moisture sensitive, and all operations carried out to prepare granules and formulations of this invention which contain clavulanate should be carried out  
20 under conditions of low relative humidity, e.g. less than 30% RH.

The present invention also provides a pharmaceutical formulation as described herein for use as an active therapeutic substance.

The present invention also provides a pharmaceutical formulation as described herein for use in the treatment of bacterial infections.

25 The present invention also provides the use of a formulation as described herein in the manufacture of a medicament for use in the treatment of bacterial infections.

The present invention also provides a method of treatment of bacterial infections in humans or animals which comprises the administration of an effective  
30 amount of a pharmaceutical formulation as described herein.

The invention will now be described by way of example only.

**Example 1.**

A tablet formulation comprising a matrix within which are dispersed delayed release granules of amoxycillin trihydrate in combination with potassium clavulanate.

5

**Granules.**

Granules were prepared by roller compaction of an amoxycillin trihydrate : potassium clavulanate 4:1 ww mix blended with 0.5 % magnesium stearate. This mix is fed to a Fitzpatrick Chilsonator, with a Fitzmill under the compactor and then a multiple deck sieve under the mill. The compacted flake generated at 1000 psi pressure is fed through the mill, fitted with an 0.074" aperture screen operating at a speed 2000 rpm, with knives forward. The milled granule is fed to a multideck sieve, fitted with a 1000 micron sieve, overlaying a 500 micron sieve overlying a 180 micron sieve. Fractions larger than 1000 microns and less than 180 microns are recycled. Fractions passing a 1000 micron sieve and retained on a 500 micron sieve are collected for coating.

**Coating.**

	Component	% ww
20	Granules from roller compaction	65.00
	Eudragit L30D	23.10
	Eudragit NE30D Ph. Eur	5.79
	Talc USP/Ph. Eur	5.79
	Antifoam M	0.32
25	Purified Water Ph.Eur	qs*
	Total	<u>100.00</u>

\* removed during processing.

The granules are coated with a Eudragit L30D/Eudragit NE30D suspension in a fluidised bed to produce delayed release granules.

30

**Tabletting.**

	Component	% ww
	Amox. (H <sub>2</sub> O) <sub>3</sub> : Pot. Clav. 1:1 blend(matrix)	6.25
35	Amoxycillin trihydrate (matrix)	7.50
	Coated granules	33.78
	Magnesium Stearate Ph. Eur or NF	0.50
	Microcrystalline cellulose BP or NF ]	q.s.*
	(Avicel PH 112)	]



Calcium carbonate granules *	q.s.*
Total	<u>100.00</u>

\* these two excipients are used as a 60:40 blend in a quantity to total 100%.

5 \*\* prepared as in example 2 below.

The components are screened and blended, and compressed to form oval tablets 19.0 x 9.0 mm, nominal weight 1000 mg. The formulation contains a 100/150 mg split between rapid and delayed release amoxycillin and a 25/37.5 mg split between rapid and delayed release clavulanate.

#### Example 2.

A tablet formulation comprising a matrix of amoxycillin trihydrate and clavulanate in combination, with rapid release and delayed release amoxycillin granules dispersed within the matrix.

#### Rapid-release amoxycillin granules.

Component	wt. %
Amoxycillin trihydrate BP	99.5
20 Magnesium stearate Ph. Eur.	0.5
Total	<u>100.00</u>

Granules are prepared by slugging the dry blend of components, and reducing the slugs through an Apex mill. The granules are sieved to produce 16-30 mesh material. These granules were used to prepare delayed release amoxycillin granules as below.

**Delayed-release amoxycillin granules.**

	<b>Component</b>	<b>wt. %</b>
	Rapid release amoxycillin granules	75.0
	Eudragit L30D USP	19.53
5	Propylene glycol Ph. Eur	3.14
	Talc Ph. Eur.	2.07
	Antifoam M	0.26
	Purified water Ph. Eur	q.s.*
	Total	<u>100.00</u>
10	* removed during processing.	

The rapid release amoxycillin granules are coated with Eudragit L30D coating in a fluidised bed coater.

15 **Calcium carbonate granules.**

	<b>Component</b>	<b>wt. %</b>
	Calcium carbonate (Sturcal F)	96.0
	Polyvinyl pyrrolidone (Kollidon 25)	4.0
	Water BP	q.s.*
20	Total	<u>100.00</u>
	* removed during processing.	

The calcium carbonate is wet massed with polyvinyl pyrrolidone dissolved in water. The mass is broken through a N<sup>o</sup>. 12 mesh sieve prior to drying at 100°C in a forced air oven. The dry granules are then passed through a N<sup>o</sup>. 30 mesh sieve.

**Tabletting.**

	<b>Component</b>	<b>wt. %</b>
	Amox. (H <sub>2</sub> O) <sub>3</sub> : Pot. Clav. 1:1 blend(matrix)	28.41
30	Rapid release amoxycillin granules	8.01
	Delayed release amoxycillin granules	42.55
	Magnesium stearate Ph. Eur or NF	0.50
	Microcrystalline cellulose BP or NF ] (Avicel PH 112)	q.s.*
35	Calcium carbonate granules	q.s*
	Total compression mix weight	<u>100.00</u>

These excipients are present in the ratio of 60 : 40 and a quantity taken sufficient to a total of 100 %.

The components are screened and blended, and compressed to prepare oval tablets, 19.0 x 9.0 mm, nominal weight 1100 mg. The formulation provides a 200 / 300 mg split between rapid (matrix + granules) and delayed (granules) release amoxycillin and 125 mg rapid release matrix potassium clavulanate.

5

**Claims:**

1. A pharmaceutical tablet formulation, comprising: a matrix which comprises a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor,  
5 and dispersed within said matrix, granules in a delayed release form ("delayed release granules") which comprise a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor,  
the overall tablet formulation including a  $\beta$ -lactam antibiotic and a  $\beta$ -lactamase inhibitor.  
10
2. A formulation according to claim 1 in which the matrix includes a  $\beta$ -lactamase inhibitor.
3. A formulation according to claim 1 or 2 in which the granules include a  $\beta$ -  
15 lactamase inhibitor in combination with the  $\beta$ -lactam antibiotic.
4. A formulation according to any one of claims 1, 2 or 3 in which the matrix includes dispersed within it granules ("rapid release granules"), in a form which release their content more rapidly than the delayed-release granules, which comprise  
20 a  $\beta$ -lactam antibiotic, optionally in combination with a  $\beta$ -lactamase inhibitor.
5. A formulation according to any one of the preceding claims in which the  $\beta$ -lactam antibiotic is amoxycillin.
- 25 6. A formulation according to any one of the preceding claims wherein the  $\beta$ -lactamase inhibitor is clavulanate.
7. A tablet formulation according to any one of the preceding claims in which the tablet has a matrix which comprises amoxycillin and clavulanate, dispersed  
30 within which are delayed release granules which comprise amoxycillin and clavulanate.
8. A tablet formulation according to any one of claims 1 to 6 in which the tablet has a matrix which comprises amoxycillin and clavulanate, dispersed within  
35 which are delayed release granules which comprise amoxycillin, and rapid release granules which comprise amoxycillin.

9. A tablet formulation according to claim 7 or 8 in which the overall distribution of the amoxycillin between the matrix plus rapid release granules : delayed release granules may vary between 2.5 : 1 and 1 : 2.5.
- 5 10. A tablet formulation according to any one of the preceding claims in which the matrix comprises a compact of compressed ingredients including the antibiotic and optionally present  $\beta$ -lactamase inhibitor.
- 10 11. A tablet formulation according to any one of the preceding claims wherein the delayed release granules are coated with a coating layer of a dissolution-retarding coating.
- 15 12. A method of preparing a pharmaceutical formulation according to any one of the preceding claims, comprising the steps of forming a matrix which comprises a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor, and dispersed within said matrix, delayed release granules which comprise a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor, the overall tablet formulation including a  $\beta$ -lactam antibiotic and a  $\beta$ -lactamase inhibitor.
- 20 13. A pharmaceutical formulation according to any one of the preceding claims for use as an active therapeutic substance.
- 25 14. A pharmaceutical formulation according to any one of the preceding claims for use in the treatment of bacterial infections.
15. The use of a formulation according to any one of the preceding claims in the manufacture of a medicament for use in the treatment of bacterial infections.
- 30 16. A method of treatment of bacterial infections in humans or animals which comprises the administration of an effective amount of a pharmaceutical formulation according to any one of claims 1 to 14.

# INTERNATIONAL SEARCH REPORT

Int. l. Application No  
PCT/EP 95/03151

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/43 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,92 19227 (SMITHKLINE BEECHAM PLC,UK) 12 November 1992 see claims see examples	1-16
P,A	--- WO,A,94 27557 (SMITHKLINE BEECHAM CORP.,U.S.A.) 8 December 1994 see claims see examples -----	1-16

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

16 November 1995

Date of mailing of the international search report

24.11.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Scarponi, U

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 95/03151

**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 16 is directed to a method of treatment of the human body by therapy (Rule 39.1(iv)PCT), the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/EP 95/03151

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9219227	12-11-92	AP-A- 328	23-03-94
		AU-B- 659836	01-06-95
		AU-A- 1649892	21-12-92
		BR-A- 9205948	08-11-94
		CA-A- 2102630	09-11-92
		CN-A- 1067577	06-01-93
		CZ-A- 9302379	16-03-94
		EP-A- 0585252	09-03-94
		HU-A- 67020	30-01-95
		JP-T- 6507396	25-08-94
		NO-A- 934009	05-11-93
		NZ-A- 242625	26-08-94
WO-A-9427557	08-12-94	AU-B- 7096294	20-12-94